Patent · US Active

Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone

US11254649B2 · kind B2 · utility

0Cited by

9References

15Claims

0Family size

Assignee

Exelixis, Inc. · US

Inventor

Adrian St. Clair Brown · Harlow, GB

Key dates

Filing date	Jan 17, 2020
Grant date	Feb 22, 2022
Priority date	—
Expiry date	Jan 17, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

This disclosure relates to the crystalline fumarate salt of (S)[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone. The disclosure also relates to pharmaceutical compositions comprising the crystalline fumarate salt of (S)[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone. The disclosure also relates to methods of treating cancers comprising administering to a patient in need thereof the crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.